China and US Equity Analyst

Roger Xie

10 year investment experience on public and private equity. Deep-dive fundamental research. Specialize in China and US market.

HKEx (388.HK): Aftermath of Epic Short Squeeze of Nickel Future

HKEx (388.HK): Nickel Short Squeeze Saga Backlash over LME Credibility

HKEx (388.HK): Resilient 1Q22 Earning Results Better than Feared

Hang Seng's New ESG-Themed Indexes Will Help Promote ESG in Asia (Some Thoughts On the Carbon Index)

HKEx (388.HK): Soft 4Q21 Trading Volume; Expect Muted Quarterly Earning Results

Gravity Works As WeWork Doesn't; Now Plan B

Equity Bottom-Up

<ul>
<li>The sluggish share performance of <a href="https://www.smartkarma.com/entities/hong-kong-exchanges-clearing" target="_blank" data-smartkarma-citation="entities:490:1" rel="noopener">HKEX (388 HK)</a> underscored the weak trading activities at Hong Kong, its January average daily turnover (ADT) is down 47% year-over-year.</li>
<li>Hong Kong's surging COVID cases have already accounted for more confirmed infections than all previous outbreak combined, we believe this will also dampen market sentiment short-term.</li>
<li>However, we remain bullish on HKEX (388 HK) with the view that China economy will likely rebound in 2022, which will drive the rebound of IPO activities and trading volume. </li>
</ul>


The sluggish share performance of HKEX (388 HK) underscored the weak trading activities at Hong Kong, its January average daily turnover (ADT) is down 47% year-over-year.
Hong Kong's surging COVID cases have already accounted for more confirmed infections than all previous outbreak combined, we believe this will also dampen market sentiment short-term.
However, we remain bullish on HKEX (388 HK) with the view that China economy will likely rebound in 2022, which will drive the rebound of IPO activities and trading volume. 


Qingdao Ainnovation Technology Group (2121 HK)

HKEx (388.HK): Latest COVID Outbreak Weighted Trading Activities